Meridian Bioscience Stock

Meridian Bioscience Equity

The The Equity of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 368.06 M USD. In the previous year, The Equity was 328.30 M USD — a change of 12.11% (higher).

Equity

368.06 MUSD

YoY

12.11%

Last updated:

In 2026, Meridian Bioscience's equity was 368.06 M USD, a 12.11% increase from the 328.30 M USD equity in the previous year.

The Meridian Bioscience Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
165.90 M USD
Jan 1, 2016
166.50 M USD
Jan 1, 2017
169.60 M USD
Jan 1, 2018
175.40 M USD
Jan 1, 2019
191.00 M USD
Jan 1, 2020
247.60 M USD
Jan 1, 2021
328.30 M USD
Jan 1, 2022
368.06 M USD
The Meridian Bioscience Equity history
YEAREquityYoY
368.06 MUSD+12.11%
328.30 MUSD+32.59%
247.60 MUSD+29.63%
191.00 MUSD+8.89%
175.40 MUSD+3.42%
169.60 MUSD+1.86%
166.50 MUSD+0.36%
165.90 MUSD+3.04%
161.00 MUSD
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Meridian Bioscience's Equity

Meridian Bioscience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Meridian Bioscience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Meridian Bioscience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Meridian Bioscience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Meridian Bioscience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Meridian Bioscience stock

The Equity of Meridian Bioscience is 368.06 M USD in 2026.

The Equity of Meridian Bioscience changed from 328.30 M USD to 368.06 M USD, representing a 12.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Meridian Bioscience

All Key Metrics — Meridian Bioscience